Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME   >  CORPORATE INFO >  BOARD MEETINGS
Board Meetings      
Venus Remedies Ltd.
Source DateBoard Meeting DateDetails
22-Jul-2025 01-Aug-2025 Quarterly Results
27-Jun-2025 08-Jul-2025 Inter alia, to consider and approve:- 1. To consider and approve Notice of 36th Annual General Meeting. 2. To consider and approve Board?s Report for Financial Year 2024-2025. 3. Any other business with the permission of Chair.
19-May-2025 26-May-2025 Audited Results
24-Jan-2025 04-Feb-2025 Quarterly Results
18-Oct-2024 29-Oct-2024 Quarterly Results
01-Aug-2024 13-Aug-2024 Quarterly Results & A.G.M.
18-Jul-2024 20-Jul-2024 (Cancelled) The Board Meeting to be held on 20/07/2024 Stands Cancelled.
10-Jul-2024 20-Jul-2024 Inter alia, to consider and approve: 1. To consider the appointment of independent director. 2. To finalize the date of 35th Annual General Meeting of the company. 3. Any other business with permission of the Chair.
21-May-2024 30-May-2024 Audited Results
02-Feb-2024 14-Feb-2024 Quarterly Results
30-Oct-2023 09-Nov-2023 Quarterly Results
03-Aug-2023 14-Aug-2023 Quarterly Results
05-Jul-2023 14-Jul-2023 VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/07/2023 ,inter alia, to consider and approve This is to inform you that the meeting of Board of Directors is scheduled to be held on 14th July 2023 inter alia: 1. To consider the appointment of Statutory Auditor of the Company. 2. To finalize the date of 34th Annual General Meeting of the company. 3. Any other business with permission of the Chair.
17-May-2023 29-May-2023 Audited Results
19-Jan-2023 30-Jan-2023 Quarterly Results
02-Nov-2022 12-Nov-2022 Quarterly Results
25-Jul-2022 30-Jul-2022 Quarterly Results
16-May-2022 27-May-2022 Audited Results
20-Jan-2022 31-Jan-2022 Quarterly Results
23-Dec-2021 30-Dec-2021 Inter alia, to consider the appointment of additional director Independent director.
Page 1 of 7
Prev || Next
Disclaimer | Privacy Policy | Grievance | FAQ | Sitemap | Client Registration | Useful Links| Anti Money Laundering | Inactive Client Policy | Scores
Vernacular Kyc | Advisory For Investors | Investor Adviser | Filing complaints on SCORES - Easy & quick | Policy on PMLA | Publishing of investor charter information | Annexure A – Investor charter of brokers | Annexure A – Investor charter of DP | Annexure B –Linked content for information to charter for DP | Annexure B & C (investor complaint data) broker & DP | Investor Charter & Complaints | Advisory-KYC Compliance | E-Voting NSE | E-Voting BSE | Details of Client Bank Accounts | Risk Disclosure | NSE FO Risk disclosure | Details of Research Analyst
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: Click Here.